Diffusing Alpha Radiation Therapy for Malignant Tumors

Study start date: March 22, 2023

Inclusion Criteria: * Subjects with any malignancy * Subjects with a tumor size ≤ 7 centimeters in the longest diameter * Subjects over 18 years old * Subjects' life expectancy is more than 6 months * Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test and are required to use an acceptable contraceptive method to prevent pregnancy for 3 months after treatment. * Subjects/Surrogate decision maker are willing to sign an informed consent form Exclusion Criteria: * Known hypersensitivity to any of the components of the treatment. * Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 12 months. * Any medical or psychiatric illness which in the opinion of the investigator would compromise the patient's ability to tolerate this treatment or interfere with the study endpoints. * Volunteers participating in another interventional study in the past 30 days which might conflict with the endpoints of this study or the evaluation of response or toxicity of DaRT. * Patients must agree to use adequate contraception (vasectomy or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapy. * High probability of protocol non-compliance (in opinion of investigator). * Subjects/Surrogate decision maker not willing to sign an informed consent. * Women who are pregnant or breastfeeding.